Stock DBI DEUTSCHE BIOTECH INNOVATIV AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Deutsche Biotech Innovativ AG Deutsche Boerse AG

Equities

DBI

DE000A0Z25L1

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG
Other stock markets
 15:13:44 2023-09-26 EDT 		5-day change 1st Jan Change
5.05 EUR -.--% Intraday chart for Deutsche Biotech Innovativ AG -.--% -.--%
2023 Deutsche Biotech Innovativ AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2018 Adrenomed AG announced that it has received €24.2 million in funding from Deutsche Biotech Innovativ AG, Wellington Ventures, HBM Healthcare Investments Ltd., and other investors CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 66.31 66.78 85.26 74.36 82.89 25.39
Enterprise Value (EV) 1 66.17 66.64 85.14 74.33 82.87 25.38
P/E ratio -261 x -404 x -211 x - -371 x -107 x
Yield - - - - - -
Capitalization / Revenue 303 x 555 x - - - -
EV / Revenue 302 x 554 x - - - -
EV / EBITDA -274 x -414 x -959 x -200 x -417 x -3,019 x
EV / FCF -503 x -894 x 806 x 146 x 497 x -61.2 x
FCF Yield -0.2% -0.11% 0.12% 0.68% 0.2% -1.63%
Price to Book 31.6 x 34.6 x 55.9 x - 90.3 x 37.3 x
Nbr of stocks (in thousands) 947 947 947 947 947 947
Reference price 2 70.00 70.50 90.00 78.50 87.50 26.80
Announcement Date 18-05-02 19-06-28 20-08-13 23-06-05 23-06-05 23-06-05
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.2188 0.1204 - - - -
EBITDA 1 -0.2416 -0.1611 -0.0887 -0.371 -0.1985 -0.008406
EBIT 1 -0.2446 -0.1641 -0.0894 -0.373 -0.2015 -0.1104
Operating Margin -111.79% -136.33% - - - -
Earnings before Tax (EBT) 1 -0.254 -0.1654 -0.4045 -0.385 -0.2233 -0.2364
Net income 1 -0.254 -0.1654 -0.4045 -0.385 -0.2233 -0.2364
Net margin -116.08% -137.39% - - - -
EPS 2 -0.2682 -0.1746 -0.4270 - -0.2357 -0.2496
Free Cash Flow 1 -0.1316 -0.0745 0.1056 0.5091 0.1667 -0.4146
FCF margin -60.14% -61.9% - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 18-05-02 19-06-28 20-08-13 23-06-05 23-06-05 23-06-05
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 0.14 0.14 0.11 0.03 0.02 0.01
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.13 -0.07 0.11 0.51 0.17 -0.41
ROE (net income / shareholders' equity) -11.8% -8.21% -23.4% -28.9% -21.7% -29.6%
ROA (Net income/ Total Assets) -6.82% -4.67% -2.69% -11% -5.54% -3.12%
Assets 1 3.723 3.538 15.01 3.497 4.032 7.574
Book Value Per Share 2 2.210 2.040 1.610 - 0.9700 0.7200
Cash Flow per Share 2 0.1500 0.1500 0.1200 - 0.0200 0.0100
Capex 1 0 0 - 0.01 - -
Capex / Sales 0.91% 1.66% - - - -
Announcement Date 18-05-02 19-06-28 20-08-13 23-06-05 23-06-05 23-06-05
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DBI Stock
  4. DBI Stock
  5. Financials Deutsche Biotech Innovativ AG